Five monoclonal antibodies have been tested for their ability to bind to myeloid precursor cells in normal human bone marrow. Indirect immunofluorescence and the fluorescence activated cell sorter ...was used to separate cells according to their reactivity for trial culture in vitro in order to grow granulocyte-macrophage colony forming cells (CFUc). Two antibodies (OKT3 and OKT11) which react strongly with bone marrow T lymphocytes were found to be unreactive with CFUc. YD1/23 reacts very strongly with both T and B lymphocytes but is only weakly reactive with CFUc. In contrast, OKT10 and YE2/36 did react with CFUc. The consequences of these findings and the potential clinical use of these antibodies in bone marrow transplantation are discussed.
Forty 6-week-old large white commercial turkeys were injected subcutaneously with a long-acting oxytetracycline formulation (69 mg/lb). The turkeys were divided into four groups of 10 birds each, and ...the birds in each group were bled twice at different times between 4 and 144 hours postinjection (PI) to determine serum levels of oxytetracycline. Two additional groups of turkeys were also given the long-acting oxytetracycline formulation mixed with either neomycin or a bacterin for Pasteurella multocida to determine if either of these compounds interfered with absorption of the oxytetracycline. Serum levels of oxytetracycline were 5.38 μg/ml, 1.59 μg/ml, and 0.93 μg/ml at 24, 48, and 72 hours PI, respectively, following an average dose of 69 mg/lb of body weight. These levels are all considered therapeutic. There appeared to be no interference with absorption of oxytetracycline when mixed with either neomycin or the bacterin. Tissue residues of oxytetracycline in the muscle, liver, and kidney were within tolerance levels by 3 weeks PI. /// Cuarenta pavos blancos comerciales grandes fueron inyectados vía subcutánea con una formulación de oxitetraciclina de acción prolongada (69 mg/lb). Los pavos fueron divididos en cuatro grupos de 10 animales cada uno y se tomaron muestras de sangre de cada grupo a intervalos diferentes entre las 4 y 144 horas post-inyección (PI) para determinar los niveles de oxitetraciclina en el suero. Dos de los grupos recibieron la administración de oxitetraciclina de acción prolongada mezclada con neomicina o con una bacterina contra Pasteurella multocida para determinar si estos compuestos pudieran interferir con la absorción de la oxitetraciclina. Los niveles de oxitetraciclina en el suero fueron de 5.38 μg/ml, 1.59 μg/ml y 0.93 μg/ml a las 24, 48 y 72 horas PI, respectivamente, después de una dosis promedio de 69 mg/lb de peso vivo. Todos estos niveles son considerados terapéuticos. Aparentemente no hubo interferencia con la absorción de oxitetraciclina cuando se la mezcló con neomicina o con la bacterina. Residuos tisulares de oxitetraciclina en el músculo, hígado y riñón se encontraban dentro del márgen de tolerancia a las 3 semanas PI.
The Intense Pulsed Neutron Source (IPNS) at Argonne National Laboratory is a major new useroriented facility which is now coming on line for basic research in neutron scattering and neutron radiation ...damage. This paper describes the data acquisition system which will handle data acquisition and instrument control for the time-of-flight neutron scattering instruments at IPNS. This discussion covers the scientific and operational requirements for this system, and the system architecture that was chosen to satisfy these requirements. It also provides an overview of the current system implementation including brief descriptions of the hardware and software which have been developed.
TARGET (Trial of Alternative Regimens in Glue Ear Treatment) is a multicentre UK randomized controlled trial (RCT) comparing bilateral ventilation tubes with and without adjuvant adenoidectomy ...against non‐surgical management in children with bilateral, persistent otitis media with effusion (OME). This paper compares the recruited and randomized children with those that, although eligible, were not included in the RCT for various reasons. This is necessary to identify any potential bias in the overall estimate of treatment effectiveness. At the first visit, 1315 children with OME satisfied the criteria of age (3 years 3 months−6 years 9 months), no previous ear or adenoid surgery, tympanometric evidence of fluid (bilateral B or B + C2) and a hearing loss (conductive loss in both ears of ≥20 dBHL). Of these children, 151 (11%) were not followed up because of overriding concern and 70 (5%) because of parental refusal. Of the 506 children eligible for randomization, because of persistence over 12 weeks of watchful waiting of bilateral OME with the same criteria, 20 (4%) were not randomized because of overriding concern and 75 (15%) because of parental refusal. The distribution of the potential effect modifiers was determined for each group. At the first visit, the only significant differences (P < 0.05), comparing those not recruited because of overriding concern with those recruited, were in respect of sex (61% girls compared with 52% boys) and hearing level (34.6 compared with 33.0 dBHL). At the second visit, the only significant difference involved less frequent upper respiratory tract infections (URTIs) in children whose parents refused to allow randomization (8% compared with 18% had had episodic URTI more often than once every 3 months). It is probable that the findings from the TARGET trial will translate to the entire clinic population in this age group as long as they meet the same audiometric and tympanometric criteria. The differences found can be handled by presentation of disaggregated results.
A group of 2-week-old turkey poults was inoculated with a pathogenic strain of Alcaligenes faecalis. One week later, half the group was injected with a long-acting oxytetracycline formulation. Poults ...were examined post-mortem on days 3, 5, and 10 post-treatment. Swabs were taken of the trachea, sinus, and lung of each poult. Poults were observed closely for clinical signs, and appropriate tissues were taken for histopathology. Results showed no evidence of therapeutic effect on A. faecalis infection in vivo, even though the organism was highly sensitive in vitro. Six-week-old turkeys were inoculated intramuscularly with 3.7 × 103organisms of the P-1059 strain of Pasteurella multocida. Immediately following inoculation, half the group was treated with the long-acting oxytetracycline. Ninety percent of the untreated poults were dead 72 hours postinoculation, whereas none of the treated turkeys died. No evidence of any clinical disease was observed in the treated group during the 8-day observation period. The long-acting oxytetracycline product was highly efficacious in preventing disease caused by experimental inoculation with the P-1059 strain of P. multocida.
The antihypertensive efficacy and metabolic effects of cyclopenthiazide 125 micrograms were compared with cyclopenthiazide 500 micrograms in patients with non-insulin dependent diabetes and ...hypertension in a double blind, randomized crossover study. After a 6-week placebo period 24 patients with non-insulin dependent diabetes mellitus, stabilized on diet or oral hypoglycaemic agents, who had a mean diastolic blood pressure between 90 and 120 mmHg after receiving placebo for 6 weeks were given 125 micrograms or 500 micrograms cyclopenthiazide for 12 weeks. Patients then received placebo for a further 6-week period, following which they received the alternate treatment dosage for 12 weeks. There were no differences between doses in their antihypertensive effects. While 500 micrograms significantly reduced systolic and diastolic blood pressures, only diastolic pressure was significantly reduced by 125 micrograms from pre-treatment values. The higher dose of cyclopenthiazide had greater effects on measures of diabetic control than did the 125 micrograms dose and the rise in blood glucose after 12 weeks' treatment with 500 micrograms was significantly different from pre-treatment values. Cyclopenthiazide 125 micrograms had significantly less effect on triglycerides, potassium and urate, than did 500 micrograms. Cyclopenthiazide 500 micrograms resulted in a significant fall in serum potassium from pre-treatment values. There were no intertreatment differences in the other variables measured. Cyclopenthiazide 125 micrograms is as effective as 500 micrograms in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients. The higher dose had more pronounced adverse effects on glucose control and serum concentrations of triglycerides, potassium and urate.
PDF
